



(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/55 (2006.01)
C07D 471/16 (2006.01)

(21) International Application Number:

PCT/US2024/045640

(22) International Filing Date:

06 September 2024 (06.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/537,426 08 September 2023 (08.09.2023) US
63/654,502 31 May 2024 (31.05.2024) US
63/684,749 19 August 2024 (19.08.2024) US

(71) Applicant: **MOMA THERAPEUTICS, INC.** [US/US];
20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts
02140 (US).

(72) Inventors: **MCGOWAN, Meredith A.**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **BUTLER, John R.**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **TOURE, Momar**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **WANG, Haoxuan**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **GUZI, Timothy J.**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **BAI, Yonghong**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **REUTERSHAN, Michael H.**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **YAN, Xin**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **SCHENKEL, Laurie B.**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **GAO, Cen**; c/o MOMA Therapeutics, Inc.,

20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US). **SOSA-ALVARADO, Brian Alexander**; c/o MOMA Therapeutics, Inc., 20 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140 (US).

(74) Agent: **ERLACHER, Heidi A.** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TRICYCLIC DERIVATIVES AND RELATED USES



(57) Abstract: The present disclosure relates to compounds of Formula (I'): (I'), and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating Werner Helicase (WRN) activity and may be used in the treatment of disorders in which WRN activity is implicated, such as cancer.